For its role as a bioregulator, the short peptide Cardiogen is well-documented. Fibroblasts, which are involved in tissue healing and scar formation, seem to be the principal targets of this compound. Although Cardiogen has been studied primarily for its involvement in cardiovascular problems (thus the name), studies have shown that its capacity to change fibroblast activity may also have advantages in other tissues. Furthermore, Cardiogen seems to be a synergistic peptide, boosting the efficacy of certain established medicines to improve long-term results with few adverse effects. As the last point, several early studies in rat models have shown that Cardiogen may boost apoptotic rates in tumor cells.
Heart muscle glycogen (cardiogen)
Cardiogen seems to increase the number of cardiomyocytes while decreasing the number of fibroblasts in the heart. The risk of cardiac remodeling leading to heart failure is reduced, and long-term results are enhanced. In addition, Cardiogen may reduce p53 protein expression, reducing apoptosis rates.
Cancer and Cardiogen
Cardiogen inhibits apoptosis in heart cells by suppressing p53 expression, although it may have the reverse effect on tumor cells. There is evidence from studies conducted in rat models of M-1 sarcoma that Cardiogen treatment increases the apoptosis rate in tumor cells. Not only that, but the impact seems to vary on a dose, suggesting that the biological effect is genuine. Since tumor cells have an abnormally high and varied vascular supply, the peptide may be somewhat selective for them. This suggests that Cardiogen has the potential to be used as a targeted therapy for cancer. In addition, the peptide may prove to be a highly effective addition to the armory against cancer if it boosts the activity of traditional cancer medicines (as it does in the treatment of heart disease).
Researchers have collaborated with Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medicine. They have extensive experience studying the effects of amino acids and short peptides on cancer and healthy tissues as they become dysfunctional and precancerous. Since they’ve been working on getting Cardiogen approved in Russia, it’s the next best option for dealing with sarcoma there.
Cardiogen and the Prostate
Prostate fibroblasts have been shown in tissue cultures to have their signaling factor expression modified by Cardiogen and other related peptides. Prostate cancer growth and progression may be influenced by elevated levels of these signaling factors, which help create a nurturing tumor microenvironment. Prostate cancer is prevalent in older males but uncommon in younger males. This disparity may be explained by the fact that the production of these markers is considerably changed in aging and senescent fibroblasts. Research has shown that Cardiogen may restore levels of these signaling molecules to those observed in young cell cultures, indicating it may help prevent prostate cancer and slow its growth.
Summary of Cardiogen
Although Cardiogen has had less study put into it than other bioregulators, it nevertheless seems to have significant impacts on many different tissues across the body. In addition, the peptide shows promise as a potential therapy for sarcoma and maybe other forms of cancer. Cardiogen seems most helpful in heart attack, hypertension, and chronic heart failure. It has positive effects on its own and enhances the efficacy of standard therapies. Buy Cardiogen peptide if you are a researcher interested in using this compound as the item of further research.
